HighTower Advisors LLC Acquires New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

HighTower Advisors LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,485 shares of the medical equipment provider’s stock, valued at approximately $607,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LNTH. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after purchasing an additional 796,000 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Lantheus in the second quarter valued at $26,794,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Lantheus during the third quarter valued at $25,955,000. LSV Asset Management grew its position in shares of Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock worth $51,462,000 after acquiring an additional 139,647 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Lantheus by 142.8% in the 2nd quarter. Renaissance Technologies LLC now owns 215,431 shares of the medical equipment provider’s stock worth $17,297,000 after acquiring an additional 126,700 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $91.94 on Friday. The stock’s 50 day moving average price is $96.95 and its 200 day moving average price is $98.23. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of 15.30 and a beta of 0.45. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LNTH. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday. They issued a “buy” rating and a $143.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.